In recent company developments, MAIA Biotechnology, Inc., a pharmaceutical preparations company valued at $54.93 million, has ...

Learn more about whether Biogen Inc. or Neurocrine Biosciences, Inc. is a better investment based on AAII's A+ Investor grades, which compare both companies' key financial metrics.

Want to stay on top of the science and politics driving biotech today? Sign up to get our biotech newsletter in your inbox. Good morning. We get into more ...

Of course, there are countless value stocks that are worth mentioning, but this is a concise list of the top 3 undervalued stocks in the Biotechnology industry for Wednesday, February 05, 2025. Let’s ...

Aurion Biotech, Inc. plans $100M IPO for corneal disease treatments, limited competition, Phase 1/2 trials underway with ...

Collaboration to explore the immunoregulation of NK and T cells within the tumor microenvironment (TME) by CAPTN-3, with the goal of enhancing ...

Immunome, Inc. (NASDAQ:IMNM) shares fell sharply by 9.6% following the announcement of the pricing of its upsized public ...

The post-consolidated Common Shares are delivered by the Company’s transfer agent to shareholders holding book shares ... a clinical-stage biotechnology company that develops novel immunotherapies to ...

If the 118th Congress does not reauthorize the farm bill, it will be incumbent upon the 119 th Congress to pass an updated farm bill as quickly as possible. The farm bill is a critical tool for ...

They show that he plans to divest stock holdings, including stakes in biotech firms CRISPR Therapeutics AG and Dragonfly Therapeutics. He’s also stepping down from roles at his law firm and at ...